Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | CA9 | Q16790 | 6/20 | 0.55 |
| ▸ | CA12 | O43570 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | MMP14 | P50281 | 2/20 | 0.50 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569419 | 0.77 | MMP2 (0.58) | MMP2CA2CA9CA12CA1 | |
| SCHEMBL569418 | 0.76 | MMP2 (0.69) | MMP2CA2CA9CA12CA1 | |
| SCHEMBL569326 | 0.76 | MMP2 (0.93) | MMP2CA2CA9CA12CA1 | |
| SCHEMBL570169 | 0.72 | MMP2 (1.00) | MMP2CA2CA9CA12CA1 | |
| SCHEMBL20282176 | 0.71 | MMP2 (0.64) | MMP2CA2CA9CA12CA1 | |
| SCHEMBL569559 | 0.70 | CA1 (0.65) | MMP2CA2CA9CA12CA1 | |
| SCHEMBL569562 | 0.70 | CA12 (0.65) | MMP2CA2CA9CA12CA1 | |
| SCHEMBL569947 | 0.70 | CA12 (0.65) | MMP2CA2CA9CA12CA1 | |
| SCHEMBL10029051 | 0.69 | MMP2 (0.71) | MMP2CA2CA9CA12CA1 | |
| SCHEMBL5445420 | 0.69 | MMP2 (0.61) | MMP2CA2CA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993544-B2 | Carbamoylphosphonates as inhibitors and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2015-03-31 | — | — | US | disclosed |
| EP-2393495-B1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RES DEV CO (IL) | 2014-07-23 | — | — | EP | disclosed |
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2012-02-09 | — | — | US | disclosed |
| EP-2393495-A1 | CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089752-A1 | CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | MMP9, MMP26, MMP25 | MMP2 10/4885CA2 91/4885CA9 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.